Plain-English translation of NCT06158919 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether combining fruquintinib with an immune-boosting medication (either nivolumab or sindilizumab) and chemotherapy can help treat advanced gastric and esophagogastric junction cancer that cannot be removed by surgery. The three-drug combination is being tested to see if it can shrink tumors and help patients live longer. Researchers want to understand both how well this combination works and what side effects patients experience.
Advanced stomach cancer is difficult to treat and often returns after surgery. This medication and others like it have shown promise in early studies, but doctors want to know whether combining them together—pairing the immune-boosting drug with fruquintinib and standard chemotherapy—might work better than current treatments.
You likely qualify if…
You likely don't qualify if…
You would receive 6 cycles of combined treatment, with each cycle lasting 3 weeks. During this phase, you would take fruquintinib as a daily pill for 14 days of each cycle, receive an intravenous infusion of the immune-boosting medication on day 1, and receive chemotherapy intravenously on day 1 along with oral chemotherapy pills for 14 days. After the 6 cycles, you would move to maintenance treatment, taking fruquintinib and the immune-boosting medication with one chemotherapy option (either as a pill or capsule) until your cancer progresses or side effects become too difficult to manage. The immune-boosting medication would continue for up to 24 months total. You would have regular visits for blood tests, imaging scans, and check-ups to monitor how you are doing.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China